» Articles » PMID: 24826805

MicroRNAs in Lupus

Overview
Journal Autoimmunity
Date 2014 May 16
PMID 24826805
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus is a prototypic autoimmune disease characterized by the production of an array of pathogenic autoantibodies, including high-affinity anti-dsDNA IgG antibodies, which play an important role in disease development and progression. Lupus preferentially affects women during their reproductive years. The pathogenesis of lupus is contributed by both genetic factors and epigenetic modifications that arise from exposure to the environment. Epigenetic marks, including DNA methylation, histone post-translational modifications and microRNAs (miRNAs), interact with genetic programs to regulate immune responses. Epigenetic modifications influence gene expression and modulate B cell functions, such as class-switch DNA recombination, somatic hypermutation and plasma cell differentiation, thereby informing the antibody response. Epigenetic dysregulation can result in aberrant antibody responses to exogenous antigens or self-antigens, such as chromatin, histones and dsDNA in lupus. miRNAs play key roles in the post-transcriptional regulation of most gene-regulatory pathways and regulate both the innate and adaptive immune responses. In mice, dysregulation of miRNAs leads to aberrant immune responses and development of systemic autoimmunity. Altered miRNA expression has been reported in human autoimmune diseases, including lupus. The dysregulation of miRNAs in lupus could be the result of multiple environmental factors, such as sex hormones and viral or bacterial infection. Modulation of miRNA is a potential therapeutic strategy for lupus.

Citing Articles

Bidirectional Interplay Among Non-Coding RNAs, the Microbiome, and the Host During Development and Diseases.

Nai S, Song J, Su W, Liu X Genes (Basel). 2025; 16(2).

PMID: 40004537 PMC: 11855195. DOI: 10.3390/genes16020208.


MicroRNA as a potential biomarker for systemic lupus erythematosus: pathogenesis and targeted therapy.

Naithani U, Jain P, Sachan A, Khare P, Gabrani R Clin Exp Med. 2023; 23(8):4065-4077.

PMID: 37921874 DOI: 10.1007/s10238-023-01234-7.


The emerging role of noncoding RNAs in systemic lupus erythematosus: new insights into the master regulators of disease pathogenesis.

Nour M, Ghorbaninezhad F, Asadzadeh Z, Baghbanzadeh A, Hassanian H, Leone P Ther Adv Chronic Dis. 2023; 14:20406223231153572.

PMID: 37035097 PMC: 10074641. DOI: 10.1177/20406223231153572.


Analysis of microRNA-199a-3p expression in CD4 T cells of systemic lupus erythematosus.

Wang H, Geng G, Zhang D, Han F, Ye S Clin Rheumatol. 2023; 42(6):1683-1694.

PMID: 36763225 DOI: 10.1007/s10067-023-06534-7.


Effects of high fat diet-induced obesity on pathophysiology, immune cells, and therapeutic efficacy in systemic lupus erythematosus.

Choi E, Kim H, Jung Y, Go H, Seong J Sci Rep. 2022; 12(1):18532.

PMID: 36323742 PMC: 9630451. DOI: 10.1038/s41598-022-21381-3.


References
1.
Lofgren S, Frostegard J, Truedsson L, Pons-Estel B, DAlfonso S, Witte T . Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun. 2012; 13(3):268-74. PMC: 3640319. DOI: 10.1038/gene.2011.84. View

2.
Ballestar E . Epigenetic alterations in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2011; 7(5):263-71. DOI: 10.1038/nrrheum.2011.16. View

3.
Schatz D, Ji Y . Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol. 2011; 11(4):251-63. DOI: 10.1038/nri2941. View

4.
Yang J, Lai E . Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol Cell. 2011; 43(6):892-903. PMC: 3176435. DOI: 10.1016/j.molcel.2011.07.024. View

5.
Koralov S, Muljo S, Galler G, Krek A, Chakraborty T, Kanellopoulou C . Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008; 132(5):860-74. DOI: 10.1016/j.cell.2008.02.020. View